@Article{,
AUTHOR = {Kelvin A. Moses, Andrew Winer, John P. Sfakianos, 
Stephen A. Poon, Matthew Kent, Melanie Bernstein, 
Paul Russo, Guido Dalbagni},
TITLE = {Contemporary management of penile cancer: greater than 15 year MSKCC experience},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {21},
YEAR = {2014},
NUMBER = {2},
PAGES = {7201--7206},
URL = {http://www.techscience.com/CJU/v21n2/61502},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Penile cancer is a rare malignancy, and few guidelines are available to define treatment paradigms. For greater understanding of the natural history of surgically treated penile cancer, we analyzed the experience at our institution.
<br/>
<b>Materials and methods:</b> Using an institutional database, we identified 127 patients treated for squamous cell carcinoma of the penis from 1995-2011. Cancer-specific survival (CSS) was calculated using the Kaplan-Meier method. Survival data were compared using the log-rank test. The difference in risk of cancer-specific death by lymph node status and histological grade was determined by univariate Cox regression analysis.
<br/>
<b>Results:</b> Five year CSS for pTis, pT1, pT2, and pT3/4 was 100%, 84% (95% CI 58%-95%), 54% (95% CI 33%-71%), and 54% (95% CI 25%-76%), respectively (p ≤ .005). Three year CSS for patients with N0, N+, and Nx disease was 90% (95% CI 47%-99%), 65% (95% CI 47%-79%), and 86% (95% CI 73%-93%), respectively (p = .03). The receipt of neoadjuvant chemotherapy did not change per 5 year period over the 16 years of our study. Median follow up was 2.8 years.
<br/>
<b>Conclusions:</b> Penile cancer patients with advanced disease had poor survival. Tumor stage and nodal status were significant predictors of CSS. Penis-sparing approaches may be considered for most patients; however, pathological stage and grade dictate the management and ultimate outcome. Further studies are necessary to clarify the benefits of chemotherapy in this disease.},
DOI = {}
}